Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form
Reexamination Certificate
2003-04-21
2009-11-03
Silverman, Eric E. (Department: 1618)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Reexamination Certificate
active
07611722
ABSTRACT:
A solid dosage form for oral administration to a patient comprising a core tablet sheathed in an annular body of compressed powder or granular material is provided. A preferred embodiment of the solid dosage form reduces contact of the active ingredient in solid form with the mucosa lining the gastrointestinal tract, which is particularly advantageous for delivering an ulcerative drug. A tool set comprising a columnar punch and a punch assembly comprising an annular punch and core rod, and a tableting process for making the solid dosage form are also provided.
REFERENCES:
patent: 1609460 (1926-12-01), Buttles
patent: 3146169 (1964-08-01), Stephenson et al.
patent: 3149375 (1964-09-01), Gehl
patent: 3977404 (1976-08-01), Theeuwes
patent: 3995631 (1976-12-01), Higuchi et al.
patent: 4061453 (1977-12-01), DeSantis
patent: 4382892 (1983-05-01), Hayakawa et al.
patent: 4639338 (1987-01-01), Stahl et al.
patent: 4839177 (1989-06-01), Colombo et al.
patent: 5051505 (1991-09-01), Park et al.
patent: 5053407 (1991-10-01), Hayakawa et al.
patent: 5071607 (1991-12-01), Ayer et al.
patent: 5074857 (1991-12-01), Shepherd et al.
patent: 5088915 (1992-02-01), Korsch et al.
patent: 5155223 (1992-10-01), Preiss
patent: 5156850 (1992-10-01), Wong et al.
patent: 5234646 (1993-08-01), Tanino et al.
patent: 5256046 (1993-10-01), Korsch et al.
patent: 5277570 (1994-01-01), Siggers
patent: 5358941 (1994-10-01), Bechard et al.
patent: 5422123 (1995-06-01), Conte et al.
patent: 5425950 (1995-06-01), Dandiker et al.
patent: 5431920 (1995-07-01), Bechard
patent: 5462427 (1995-10-01), Kramer
patent: 5498147 (1996-03-01), Katagiri et al.
patent: 5539110 (1996-07-01), Kim et al.
patent: 5551856 (1996-09-01), Katagiri
patent: 5582838 (1996-12-01), Rork et al.
patent: 5607704 (1997-03-01), Schlierenkämper et al.
patent: 5635223 (1997-06-01), Korsch et al.
patent: 5653926 (1997-08-01), Bogue et al.
patent: 5672364 (1997-09-01), Kato et al.
patent: 5681590 (1997-10-01), Bechard et al.
patent: 5698149 (1997-12-01), Hinzmann et al.
patent: 5804570 (1998-09-01), Santora, II et al.
patent: 5882656 (1999-03-01), Bechard et al.
patent: 5908959 (1999-06-01), Kubela et al.
patent: 5910324 (1999-06-01), Koch
patent: 5994324 (1999-11-01), Ashida et al.
patent: 5994329 (1999-11-01), Daifotis et al.
patent: 5994377 (1999-11-01), Kim et al.
patent: 6004120 (1999-12-01), Matsubara et al.
patent: 6008207 (1999-12-01), Brenner et al.
patent: 6015801 (2000-01-01), Daifotis et al.
patent: 6090410 (2000-07-01), Bechard et al.
patent: 6113887 (2000-09-01), Mori et al.
patent: 6194004 (2001-02-01), Bechard et al.
patent: 6201148 (2001-03-01), Lidor-Hadas et al.
patent: 6225294 (2001-05-01), Daifotis et al.
patent: 6264985 (2001-07-01), Cremer
patent: 6281381 (2001-08-01), Finkelstein et al.
patent: 6358970 (2002-03-01), Duggan et al.
patent: 6399592 (2002-06-01), Whiteford
patent: 6406714 (2002-06-01), Bechard et al.
patent: 6413955 (2002-07-01), Askew et al.
patent: 6414006 (2002-07-01), Harada et al.
patent: 6416737 (2002-07-01), Manolagas et al.
patent: 6432931 (2002-08-01), Reszka et al.
patent: 6465017 (2002-10-01), Tomer et al.
patent: 6476006 (2002-11-01), Flashner-Barak et al.
patent: 6544967 (2003-04-01), Daifotis et al.
patent: 6562974 (2003-05-01), Cazer et al.
patent: 6573401 (2003-06-01), Bosch i Lladóet al.
patent: 6586457 (2003-07-01), Harada et al.
patent: 6620358 (2003-09-01), Voss
patent: 6623755 (2003-09-01), Chen et al.
patent: 6627221 (2003-09-01), Gabel et al.
patent: 6645974 (2003-11-01), Hutchinson et al.
patent: 6696601 (2004-02-01), Finkelstein et al.
patent: 6863901 (2005-03-01), Hirsh et al.
patent: 6924389 (2005-08-01), Jackstell et al.
patent: 6963008 (2005-11-01), Finkelstein et al.
patent: 7009071 (2006-03-01), Dabak et al.
patent: 7038083 (2006-05-01), Lidor-Hadas et al.
patent: 7112577 (2006-09-01), Hamied et al.
patent: 2001/0036475 (2001-11-01), Chen et al.
patent: 2001/0051616 (2001-12-01), Karpf et al.
patent: 2002/0052527 (2002-05-01), Lidor-Hadas et al.
patent: 2002/0151459 (2002-10-01), Bergstrom et al.
patent: 2002/0169148 (2002-11-01), Yates
patent: 2003/0032629 (2003-02-01), Daifotis et al.
patent: 2003/0203878 (2003-10-01), Flashner-Barak et al.
patent: 2005/0026871 (2005-02-01), Flashner-Barak et al.
patent: 2005/0113343 (2005-05-01), Sienkiewicz et al.
patent: 2005/0113602 (2005-05-01), Kessinger et al.
patent: 2005/0181043 (2005-08-01), Nandi et al.
patent: 2005/0256334 (2005-11-01), Welz-Biermann et al.
patent: 2005/0288509 (2005-12-01), De Ferra et al.
patent: WO 94/14455 (1994-07-01), None
patent: WO 96/19201 (1996-06-01), None
patent: WO 98/23263 (1998-06-01), None
patent: WO 98/56360 (1998-12-01), None
patent: WO 00/04924 (2000-02-01), None
patent: WO 00/49026 (2000-08-01), None
patent: WO 03/007916 (2003-01-01), None
patent: WO 03/057136 (2003-07-01), None
patent: WO 03/064438 (2003-08-01), None
patent: WO 03/093282 (2003-11-01), None
patent: WO 03/097655 (2003-11-01), None
patent: WO 2005/035542 (2005-04-01), None
A.A. al-Quorain et al., “Non Steroidal Anti-inflammatory Drug Induced Gastropathy: a Comparative Endoscopic and Histopathological Evaluation of the Effects of Tenoxicam and Diclofenac,” J. Int. Med. Res. 1993, 21(2), 89-97.
P.M. Goggin et al., “Prevalence ofHelicobacter PyloriInfection and its Effect on Symptoms and non-Steroidal Anti-inflammatory Drug Induced Gastro-intestinal Damage in Patients with Rheumatoid Arthritis,” Gut 1993, 34(12), 1677-80.
M. Frezza et al., “The Histopathology of Non-Steroidal Anti-inflammatory Drug Induced Gastroduodenal Damage: Correlation withHelicobacter Pylori, Ulcers and Haemorrhagic Events,” J. Clin. Pathol. 2001, 54(7), 521-5.
K.O. Larsen, “Oesophagusskader Relatert til Bisfosfonater,” Tidsskr. Nor. Lægeforen 2000, 120(2), 2397-9.
D.Y. Graham et al., “Alendronate and Naproxen Are Synergistic for Development of Gastric Ulcers,” Arch. Intern. Med. 2001, 161(1), 107-110.
F.L. Lanza et al., “Endoscopic Comparison of Esophageal and Gastroduodenal Effects of Risedronate and Alendronate in Postmenopausal Women,” Gastroenterology 2000, 119(3), 631-8.
D.C. Bauer et al., “Upper Gastrointestinal Tract Safety Profile of Alendronate: the Fracture Intervention Trial,” Arch. Intern. Med. 2000, 160(4), 517-25.
J.K. Marshall et al., “A Randomized Controlled Trial to Assess Alendronate-associated Injury of the Upper Gastrointestinal Tract,” Aliment. Pharmacol. Ther. 2000, 14(11), 1451-7.
D.Y. Graham et al., “Alendronate Gastric Ulcers,” Aliment. Pharmacol. Ther. 1999, 13(4), 515-9.
S.C. Abraham et al., “Alendronate-associated Esophageal Injury:pathologic and Endoscopic Features,” Mod. Pathol. 1999, 12(12), 1152-7.
S.N. Elliott et al., “Alendronate Induces Gastric Injury and Delays Ulcer Healing in Rodents,” Life Sci. 1998, 62(1), 77-91.
D.Y. Graham, “Excess Gastric Ulcers are Associated with Alendronate Therapy,” Am. J. Gastroenterol. 1998, 93(8), 1395-6.
R.E. Colina et al., “A New Probable Increasing Cause of Esophageal Ulceration: Alendronate,” Am. J. Gastroenterol. 1997, 92(4), 704-6.
D. Jasperson, “Drug Induced Oesophageal Disorders:pathogenesis, Incidence, Prevention and Management,” Drug Saf. 2000, 22(3), 237-249.
S.J. Smith et al., “Pill-induced Esophagitis Caused by Oral Rifampin,” Ann.Pharmocother. 1999, 33(1), 27-31.
J.W. Kikendall, “Pill Esophagitis,” J. Clin. Gastroenterol. 1999, 28(4), 298-305.
A. Minocha et al., “Pill Esophagitis Caused by Non-steroidal Antiinflammatory Drugs,” Am. J. Gasterenterol. 1991, 86(8), 1086-9.
A.C. Perkins et al., “The Use of Scintigraphy to Demonstrate the Rapid Esophageal Transit of the Oval Film-coated Placebo Risedronate Tablet Compared to a Round Uncoated Placebo Tablet When Administered with Minimal Volumes of Water,” Int. J. Pharm, 2001, 222(2) 295-303.
V. Simko et al., “Increased Risk in Esophageal Obstruction with Slow Release Med
Aqua Ofer
Fleshner-Barak Moshe
Lerner E. Itzhak
Rosenberger Vered
Kenyon & Kenyon LLP
Silverman Eric E.
Teva Pharmaceutical Industries Ltd.
LandOfFree
Dosage form with a core tablet of active ingredient sheathed... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dosage form with a core tablet of active ingredient sheathed..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dosage form with a core tablet of active ingredient sheathed... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4082508